logo
Amphastar Pharmaceuticals to Release First Quarter Earnings and Hold Conference Call on May 7th, 2025

Amphastar Pharmaceuticals to Release First Quarter Earnings and Hold Conference Call on May 7th, 2025

Yahoo30-04-2025

RANCHO CUCAMONGA, CA / / April 30, 2025 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced that the Company will release results for its first quarter of 2025 ended March 31, 2025, after the market closes on Wednesday, May 7th, 2025, and will hold a conference call to discuss its financial results at 2:00 p.m. Pacific Time.
To access the conference call, dial toll free 877-407-0989, for international calls, dial 201-389-0921, ten minutes before the conference.
The call can also be accessed on the Investors page on the Company's website www.amphastar.com. The webcast replay of the call will be available on our Company website within 24 hours after the end of the live conference call.
Company Information
Amphastar is a bio-pharmaceutical company that focuses primarily on developing, manufacturing, marketing, and selling technically challenging generic and proprietary injectable, inhalation, and intranasal products. Additionally, the Company sells insulin API products. Most of the Company's finished products are used in hospital or urgent care clinical settings and are primarily contracted and distributed through group purchasing organizations and drug wholesalers. More information and resources are available at www.amphastar.com.
Forward Looking Statements
All statements in this press release and in the conference call referenced above that are not historical are forward-looking statements, including, among other things, statements relating to our expectations regarding future financial performance and business trends, our future growth, sales and marketing of our products, market size and expansion, product portfolio, product development, the timing of FDA filings or approvals, including the DMFs of ANP, the timing of product launches, acquisitions and other matters related to our pipeline of product candidates, the timing and results of clinical trials, the benefits BAQSIMI®, including its potential for continued revenue growth, the strategic trajectory of and market for our product pipeline, our ability to leverage our existing expertise and technology, and other future events. These statements are not facts but rather are based on Amphastar's historical performance and our current expectations, estimates, and projections regarding our business, operations, and other similar or related factors. Words such as "may," "might," "will," "could," "would," "should," "anticipate," "predict," "potential," "continue," "expect," "intend," "plan," "project," "believe," "estimate," and other similar or related expressions are used to identify these forward-looking statements, although not all forward-looking statements contain these words. You should not place undue reliance on forward-looking statements because they involve known and unknown risks, uncertainties, and assumptions that are difficult or impossible to predict and, in some cases, beyond Amphastar's control. Actual results may differ materially from those in the forward-looking statements as a result of a number of factors, including those described in Amphastar's filings with the Securities and Exchange Commission, including in our Annual Report on Form 10-K for the year ended December 31, 2024, filed with the SEC on March 3, 2025 and our other filings or reports that we may file with the SEC. In particular, there can be no guarantee that our sales strategies will be successful, or that we will continue to experience significant sales of BAQSIMI®. You can locate these reports through our website at http://ir.amphastar.com and on the SEC's website at www.sec.gov. The forward-looking statements in this release speak only as of the date of the release. Amphastar undertakes no obligation to revise or update information or any forward-looking statements in this press release or the conference call referenced above to reflect events or circumstances in the future, even if new information becomes available or if subsequent events cause our expectations to change.
Contact:
Bill PetersChief Financial Officer(909) 476-3416
SOURCE: Amphastar Pharmaceuticals, Inc.
View the original press release on ACCESS Newswire

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

NanoHive Medical Sublicenses DirectSync's Piezoelectric Patents to Explore Development of Hive™ Soft Titanium® 3D Printed Spine Interbody Fusion "Smart Implant"
NanoHive Medical Sublicenses DirectSync's Piezoelectric Patents to Explore Development of Hive™ Soft Titanium® 3D Printed Spine Interbody Fusion "Smart Implant"

Yahoo

time20 minutes ago

  • Yahoo

NanoHive Medical Sublicenses DirectSync's Piezoelectric Patents to Explore Development of Hive™ Soft Titanium® 3D Printed Spine Interbody Fusion "Smart Implant"

BOSTON, June 10, 2025 /PRNewswire/ -- NanoHive Medical, LLC, a leading innovative 3D printed spinal implant technology company is pleased to announce that the company has secured the exclusive sublicense of DirectSync Surgical's piezoelectric implantable sensor technology for the field of spinal fusion. DirectSync Surgical had licensed the technology from the University of Kansas. NanoHive is exploring the advancement of successful proof-of-concept research to potentially develop bone stimulating and remote monitoring/data collection sensor technology housed in the company's highly innovative spinal interbody fusion device lattice which is currently commercialized in the company's Hive™ Soft Titanium® portfolio of 3D printed spinal interbody fusion devices. In October 2023, the company reported the initiation of a research collaboration with DirectSync Surgical. Based on the preliminary research generated, the company ascertained that their proprietary rhombic dodecahedron lattice technology was uniquely capable of transferring significant energy from the encapsulated piezoelectric sensor. The company is currently in the process of working with the US Food and Drug Administration (FDA) on the transfer of the Breakthrough Device Designation from DirectSync to NanoHive. Patrick O'Donnell, President & CEO of NanoHive stated, "NanoHive's Soft Titanium® technology is the ideal interbody fusion implant to deliver a sensor with data collection and bone stimulation capability. The company is excited about the prospect of leading the way with the development of a technological leap in the interbody fusion device category. Our view of the future of innovation in spine devices emphasizes that new technologies must demonstrate an improvement to patient virtual care and clinical outcomes as well as connectivity with enabling surgical technologies and artificial intelligence. These advancements must also deliver cost-efficiencies to the various stakeholders involved in the spine patient's episode-of-care. More meaningful and frequent data collection that can ultimately be utilized as a predictive tool will be essential to this vision." About NanoHive Medical LLC NanoHive Medical is a pioneer and leading innovator in 3D printed spinal interbody fusion implants and instrumentation. The company's proprietary, biomimetic Soft Titanium® technology clearly distinguishes their products in the $2.4B U.S. spinal interbody fusion device market. The Hive™ portfolio of interbody fusion devices provide surgeons and their patients ideal biomechanical elastic modulus properties, clear and precise diagnostic imaging capability, osteoblast cell attraction and integration – all features that lead to consistently strong fusion constructs and efficacious clinical experiences. NanoHive Medical is based in Woburn, Massachusetts U.S.A. Contact: Patrick O'Donnell, CEO & President, NanoHive Medical LLC, Website: About DirectSync Surgical DirectSync Surgical is a rising leader in smart patient powered implant devices. With a commitment to innovation and foundational research, the company develops and manufactures advanced tools that empower both spinal and orthopedic professionals to achieve superior surgical outcomes. DirectSync Surgical's products are not available for sale in the US. Contact: Leighton LaPierre, COO, DirectSync Surgical, leighton@ Website: NanoHive Medical, LLC | 12 Gill Street, Suite 4500 | Woburn, MA 01801 | 844-943-5433 View original content to download multimedia: SOURCE NanoHive Medical Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Applied Medical Technology, Inc. Unveils Redesigned Mobile App Aligned with Recent Website Refresh
Applied Medical Technology, Inc. Unveils Redesigned Mobile App Aligned with Recent Website Refresh

Yahoo

time20 minutes ago

  • Yahoo

Applied Medical Technology, Inc. Unveils Redesigned Mobile App Aligned with Recent Website Refresh

BRECKSVILLE, Ohio., June 10, 2025 /PRNewswire/ -- Applied Medical Technology, Inc. (AMT), a leader in innovative medical devices, is proud to announce the launch of its redesigned mobile application, AMT ONE Source®. This strategic update follows a successful website redesign completed late 2024, ensuring that both platforms now offer a cohesive, user-friendly digital experience. Enhancing User Experience Across PlatformsThe redesigned mobile app mirrors the modern, intuitive design language introduced during the website refresh. With a renewed focus on user experience and engagement, the mobile platform now features streamlined interfaces and updated information. "In today's fast-paced healthcare environment, it is essential that our digital platforms are not only reliable but also easy to navigate and visually appealing," said Bill Bentley, National Sales Manager. "Created with our youngest patients in mind, the redesign was thoughtfully developed to be more engaging, age-appropriate, and easy to navigate—helping children and their families feel more supported and empowered throughout their healthcare journey." Key Features and Benefits Unified Design Aesthetic: The mobile app adopts the clean, modern design previously launched on the website, providing a consistent look and feel across all digital touchpoints. Richer Content Experience: The app now features an expanded content database, providing a broader range of resources and information to support users with timely, relevant, and easy-to-access content. Improved Performance: The redesigned app features enhanced performance, with a new backend architecture that allows for faster content updates, easier maintenance, and more frequent improvements to keep the experience fresh and relevant. AMT partnered with Cleveland-Ohio based software company, Stream 9, on the redesign. Their strong track record in software design and development brought deep technical expertise and a strategic approach. "We're fortunate in our business to develop custom software projects for businesses of all kinds; but it's especially rewarding to work on a project that will deliver such a direct benefit to patients and their caregivers. AMT brought a clear vision to the table, and we worked closely together to translate that into a modern, scalable, and user-friendly digital experience," shared Kirk Miesle, Founder of Stream 9. The AMT ONE Source® app is available now on the App Store and Google Play. About AMT: Applied Medical Technology, Inc. (AMT) is a global leader in enteral and surgical devices committed to improving lives through innovation. For 40 years, AMT has bridged the gap between medical technology and patient needs, collaborating with healthcare professionals and users to develop high-quality, life-enhancing solutions. Our holistic approach prioritizes the well-being of the whole person, not just the device they use. View original content to download multimedia: SOURCE Applied Medical Technology, Inc.

AppLovin Investor Alert: Scott+Scott Attorneys at Law LLP Investigates AppLovin Corporation's Directors and Officers for Breach of Fiduciary Duties
AppLovin Investor Alert: Scott+Scott Attorneys at Law LLP Investigates AppLovin Corporation's Directors and Officers for Breach of Fiduciary Duties

Business Wire

time30 minutes ago

  • Business Wire

AppLovin Investor Alert: Scott+Scott Attorneys at Law LLP Investigates AppLovin Corporation's Directors and Officers for Breach of Fiduciary Duties

NEW YORK--(BUSINESS WIRE)-- Scott+Scott Attorneys at Law LLP ('Scott+Scott'), an international securities and consumer rights litigation firm, is investigating whether the leadership of AppLovin Corporation ('AppLovin') (NASDAQ: APP) breached their fiduciary duties to AppLovin and its shareholders. Scott+Scott is investigating whether members of AppLovin's board of directors (the 'Board') made, or caused AppLovin to make, false and/or misleading statements, as well as failed to disclose material adverse facts, about AppLovin's business, operations, prospects, and financial health. Specifically, Scott+Scott is investigating whether the Board failed to disclose material information, including whether: (1) AppLovin is reverse-engineering and exploiting advertising data from Meta Platforms; (2) AppLovin is using manipulative practices to drive their own ad click-through and app download rates higher; (3) that, as a result, AppLovin was inflating installation numbers and thus its profit figures; and (4) as a result, statements about AppLovin's business, operations, and prospects lacked a reasonable basis. On February 26, 2025, two short reports were published, disclosing the above information. On this news, the stock price fell over 12.2%. What You Can Do – If you own shares of AppLovin, you may have legal claims against AppLovin's directors and officers. If you wish to discuss this investigation, or have questions about this notice or your legal rights, please contact attorney Joe Pettigrew toll-free at (844) 818-6982 or jpettigrew@ About Us Scott+Scott is an international law firm known for its expertise in representing corporate clients, institutional investors, businesses, and individuals harmed by anticompetitive conduct or other forms of wrongdoings, including securities law and shareholder violations. With more than 100 attorneys in nine offices in the United States, as well as three offices in Europe, our advocacy has resulted in significant monetary settlements on behalf of our clients, along with other forms of relief. Our highly experienced attorneys have been recognized for being among the top financial lawyers in 2024 by Lawdragon, WWL: Commercial Litigation 2024, and Legal 500 in Antitrust Civil Litigation, and have received top Chambers 2024 rankings. In addition, we have been recognized by the American Antitrust Institute for the successful litigation of high-stakes anticompetitive claims in the United States. To learn more about Scott+Scott, our attorneys, or complex case resolution, please visit Attorney Advertising

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store